WallStSmart

Insmed Inc (INSM)vsVanda Pharmaceuticals Inc (VNDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 181% more annual revenue ($606.42M vs $216.10M). INSM leads profitability with a -2.1% profit margin vs -102.0%. INSM appears more attractively valued with a PEG of 1.09. VNDA earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

VNDA

Hold

39

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 6.7Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

VNDA1 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

VNDA4 concerns · Avg: 2.8/10
PEG RatioValuation
2.234/10

Expensive relative to growth rate

Market CapQuality
$403.12M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-50.9%2/10

ROE of -50.9% — below average capital efficiency

EPS GrowthGrowth
-95.9%2/10

Earnings declined 95.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : VNDA

The strongest argument for VNDA centers on Price/Book.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : VNDA

The primary concerns for VNDA are PEG Ratio, Market Cap, Return on Equity.

Key Dynamics to Monitor

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

VNDA is growing revenue faster at 7.6% — sustainability is the question.

VNDA generates stronger free cash flow (-30M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

INSM scores higher overall (39/100 vs 39/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Vanda Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company is headquartered in Washington, the District of Columbia.

Want to dig deeper into these stocks?